Genentech’s Actimmune
Executive Summary
PLA filed for the gamma interferon product on Dec. 20 for the treatment of chronic granulomatous disease (CGD), an orphan disease that affects about 250 patients in the U.S. The PLA includes data from 128 patients. Actimmune is also in Phase III trials for the treatment of infections in patients with traumatic injuries and as an adjuvant therapy in the treatment of patients with melanoma and small cell lung cancer. Other companies with gamma interferons in development include Biogen, Amgen and Chiron.